A molecular genetic approach has been employed to investigate functional interactions within 23S rRNA. Each of the three base substitutions at guanine 2032 has been made. The 2032A mutation confers resistance to the antibiotics chloramphenicol and clindamycin, which interact with the 23S rRNA peptidyltransferase loop.
substitutions were compared with and combined with a 12-bp deletion mutation in domain II and point mutations at positions 2057 and 2058 in the peptidyltransferase region of domain V that also confer antibiotic resistance. Both the domain II deletion and the 2057A mutation relieve the hypersensitive effect of the 2032A mutation, producing an erythromycin-resistant phenotype; in addition, the combination of the 2032A and 2057A mutations confers a higher level of chloramphenicol resistance than either mutation alone. 23S rRNAs containing mutations at position 2058 that confer clindamycin and erythromycin resistance become deleterious to cell growth when combined with the 2032A mutation and, additionally, confer hypersensitivity to erythromycin and sensitivity to clindamycin and chloramphenicol. Introduction of the domain II deletion into these double-mutation constructs gives rise to erythromycin resistance. The results are interpreted as indicating that position 2032 interacts with the peptidyltransferase loop and that there is a functional connection between domains II and V.
The coupling of amino acids to form proteins is an essential biological process catalyzed by the ribosomal 50S subunit. A region within domain V of the 23S rRNA, termed the peptidyltransferase center, has been conclusively shown to be involved in this process (6, 37) . This region has a phylogenetically conserved secondary structure consisting of a loop formed at the junction of five helices (20) . Highly conserved bases in the single-stranded loop have been shown by footprinting, photoaffinity labeling, and mutagenesis to interact with the aminoacyl terminus of tRNA (1, 26) and with antibiotics that inhibit peptide bond formation (6, 8, 17, 25, 37) (Fig. 1) .
Studies with one of these antibiotics, chloramphenicol, have played a major role in defining the 23S rRNA peptidyltransferase region. Chloramphenicol's only points of rRNA contact identified by footprinting are within the loop region (25) , as are mutagenized nucleotides that confer drug resistance (Fig. 1) . The antibiotic anisomycin, lincosamides, and macrolides bind to the same rRNA region as chloramphenicol, as shown by competition binding studies (35) , overlapping drug footprints (11, 25) , and multiple-drug resistance conferred by certain point mutations (16, 28) (Fig. 1) . Peptidyltransferase is unlikely, however, to be exclusively supported by this region, as several lines of evidence indicate the involvement of other rRNA structures. The aminoacyl end of tRNA protects bases within the peptidyltransferase loop against chemical modification, but there are additional effects in neighboring structures (26) . Resistance to erythromycin (a macrolide) is also conferred by deletion mutations in 23S rRNA domain II (12) , and in tobacco chloroplasts, resistance to lincomycin (a lincosamide) is conferred by a mutation at 23S rRNA nucleotide 2032 adjacent to, but distinct from, the peptidyltransferase loop (7) .
A reliable secondary structure model, confirmed by phylogenetic sequence comparisons, is available for 23S rRNA (20) . Presently, however, little is understood about how the regions discussed above are spatially oriented or how they interact to form a functionally active peptidyltransferase. In the present study, each of the three nucleotide changes at position 2032 has been made in Escherichia coli 23S rRNA. The altered tolerances towards chloramphenicol, clindamycin (7-chloro-7-deoxylincomycin), and erythromycin caused by these mutations have been evaluated and compared with resistances conferred by domain II (20) . Arrows indicate the relevant cross-linked (X-link) bases (10) and the positions photoaffinity labeled by benzophenone-derivatized Phe tRNA (PB-Phe tRNA) (1) andp-azidopuromycin (6) . Sites within this region where interaction of the tRNA 3'-end causes altered reactivities to chemical reagents (tRNA 3-end footprint) are shown (26) . Positions 31. DNA preparation, and gel electrophoresis were performed by standard procedures (27) .
Site-directed mutagenesis and plasmid construction. All plasmids used in this study are formed from plasmid pKK3535, which is a pBR322 derivative encoding ampicillin resistance, with the entire rmnB operon (Fig. 2) inserted into the tetracycline resistance gene (4) . Mutations (Fig.  2) , thereby circumventing the problem of duplicated restriction sites (13) .
The 23S RNA 2057G-+A and 2058A-T mutations on plasmids coding for the E. coli rnH operon (16, 28) were excised on 4.1-kb SalI-BamHI fragments, which were ligated with the 23S rRNA gene Sall site in rmnB to form the rrnB-rrnH fusions shown in Fig. 2b . The formation of the 2058G mutation and A12 (a 12-bp deletion of nucleotides 1219 to 1230) has been previously described (13, 36) . 23S
rRNA genes with multiple mutations were constructed by combining fragments at the unique Sall and/or KspI sites in plasmid pSK41 (Fig. 2 ). In plasmids with 2058G, rnB is truncated at the BclI site and the rnB-rmnH operon fusions are longer than rmnB; these differences in plasmid size did not affect rates of cell growth on ampicillin (Table 1) . Certain combinations of mutations proved difficult to isolate and had a slow-growth phenotype when expressed from the rnB promoters. This problem was overcome by using plasmid pLK35 (12) to modulate rRNA gene expression from the lambda PL promoter (19) (Fig. 1) Table 2 , the rrnB promoters have been replaced by the lambdapL promoter (12, 19) . Plasmid pSK41 contains the 4.3-kb XbaI-BamHI 3' portion of rrnB (13) . rates of wild-type, 2032C, or 2032U mutants at permissive levels of clindamycin (10 mg/liter). E. coli is naturally resistant to lincomycin; therefore, the growth of the mutants on this drug was not assayed. Cells formed distinct colonies after 22 h on erythromycin at a concentration of 30 mg/liter, whereas there was no growth under these conditions when the G at position 2032 was changed to A, C, or U (Table 1) . After prolonged incubation for 48 h, the 2032 mutants formed visible colonies, showing that this drug concentration is nonlethal. The 2032A mutation enabled E. coli to grow on chloramphenicol at 4 mg/liter, while cells with the 2032G or 2032C mutation were inhibited by 2 mg/liter. The 2032U mutation supported slow growth on 2 mg of chloramphenicol per liter. In the absence of antibiotics that bind to the 50S ribosomal subunit, the 2032 mutations had no effect on cell growth rate (Tables 1 and 2 ).
Other 23S RNA mutations conferring resistance to chloramphenicol, lincosamides, and macrolides. An equivalent degree of chloramphenicol resistance is conferred by 2057A and 2032A, both mutations supporting growth on chloramphenicol at 4 mg/liter. The 2058G and 2058U mutations conferred a phenotype similar to that of the 2032U mutation, each providing a distinct growth advantage on chloramphenicol at 2 mg/liter, but could not support growth at 4 mg/liter. On clindamycin, the 2058G and 2058U mutations both confer greater resistance than the 2032A mutation ( Table 1) . The 2058G and 2058U mutations also confer higher levels of erythromycin resistance than the 2057A mutation, which in turn confers better resistance than the A12 mutation (Table  1) . However, when 23S rRNA was expressed from the lambdapL promoter, the A12 mutation enabled cells to grow at higher erythromycin levels than the 2058G (Table 2 ) and 2058U mutations.
Combinations of drug resistance mutations in 23S RNA. The combination of mutations 2032A and 2057A in the same 23S RNA produced a phenotype that retains the advantageous growth characteristics of each individual mutation (Table 1) . Cells grew better on chloramphenicol with both mutations than with either mutation alone; the 2032A-encoded clindamycin resistance is retained, and the 2057A-encoded erythromycin-resistant phenotype is dominant over the 2032A-induced hypersensitivity. When mutations 2032A and 2058G (or 2058U) were combined, however, cells grew slowly in the absence of 50S subunit-specific drugs and they were incapable of growing on erythromycin even after extended incubations; cells also failed to grow on chloramphenicol and clindamycin, despite the growth advantage on these drugs conferred by each of the two mutations on its own. The rate of cell growth on ampicillin was normal when 23S RNA containing the 2032A and 2058G mutations was expressed from the lambdapL promoter, but cells remained hypersensitive to erythromycin ( Table 2) . Introduction of the A12 mutation into plasmids either with the 2032A mutation alone or with a combination of the A2032 and G2058 mutations relieved the hypersensitivity effect and conferred an erythromycin-resistant phenotype.
DISCUSSION
The sequence of the 23S rRNA peptidyltransferase loop region depicted as single stranded in Fig. 1 is highly conserved (20) . Many of these bases have been shown to interact both with the aminoacyl end of tRNA (1, 26) and with antibiotics that inhibit peptide bond formation (6, 25) (Fig. 1) . The importance for rRNA function of the neighboring stem-loop (formed by nucleotides 2023 to 2040) is indicated by its presence in all 23S-like rRNAs, including the truncated versions in mitochondria (20) . Nucleotide 2032 in the hairpin loop is conserved as a guanosine in all eubacteria and chloroplasts, and the first indication that this nucleotide is functionally connected with peptidyltransferase was revealed when Cseplo et al. identified an A transition mutation at this position in a lincomycin-resistant tobacco chloroplast (7) . (15) , and also after introduction of a mutation in 23S rRNA domain II adjacent to the site where deletions confer erythromycin resistance (9) . The mutations could be affecting drug binding, or they could be enhancing the effectiveness of erythromycin in physically blocking peptide chain elongation (35) or in aggravating premature dissociation of peptidyl-tRNA from the ribosome (24) .
Nucleotide 2032 has been cross-linked by nitrogen mustard to 2055 (10) . The proximity of these two positions suggests that the 2032A mutation could bring about its effect by altering the tertiary alignment of 2058A and/or the neighboring bases. Mutations at positions 2057 and 2058 probably also perturb the local structure. The drug resistances conferred (Table 1) show that any of these alterations on its own can be incorporated in a functionally active rRNA molecule.
The combination of the 2032A mutation and the 2057A mutation is permissible and indeed advantageous in, for example, the case of the additive chloramphenicol resistance effects. However, the combination of the 2032A mutation and the 2058G or U mutation is deleterious, indicating that the bases are a part of a finely tuned mechanism which cannot accommodate these combined structural perturbations.
UV and nitrogen mustard cross-links have been created between nucleotides 571 and 2031, 746 and 2613, and 979 to 984 and 2029 (10) (Fig. 1) , orienting positions 2032 and 2058 in the midst of domain II. A functional connection between domains II and V based on the A12 mutation that confers erythromycin resistance has previously been reported (13) . Expression of A12 23S RNA from the rnB promoters slows cell growth in the absence of erythromycin (Table 1) , probably because the deletion has a side effect on 50S subunit assembly (12) . However, the growth rate is normal when A12 23S RNA is expressed from the weaker lambdapL promoter (12) , and this construct confers better erythromycin resistance ( Table 2 ). The A12 mutation is dominant over the 2032A mutation, relieving the erythromycin-hypersensitive effect and conferring a drug-resistant phenotype essentially identical to that conferred by A12 alone (Tables 1 and 2 ). Expressed from thepL promoter, 23S rRNA with the 2032A and 2058G mutations does not cause appreciably slower growth in the absence of drugs, but erythromycin hypersensitivity is still observed ( 
